CBIO Stock Price, Catalyst Biosciences Inc Quote, Chart

Market Summary

USD21.33-0.03

Delayed

-0.14%

CBIO Stock Price

View Fullscreen

CBIO RSI Chart

CBIO Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-21.32

Price/Sales (Trailing)

16.06

EV/EBITDA

-23.9

Price/Free Cashflow

104.82

CBIO Price/Sales (Trailing)

CBIO Profitability

EBT Margin

-67.84%

Return on Equity

-612.8%

Return on Assets

-73.35%

Free Cashflow Yield

0.95%

CBIO Fundamentals

CBIO Revenue

Revenue (TTM)

113.5M

CBIO Earnings

Earnings (TTM)

-85.5M

Earnings Growth (Yr)

-192.82%

Earnings Growth (Qtr)

-5.1K%

Breaking Down CBIO Revenue

Last 7 days

8.8%

Last 30 days

4.8%

Last 90 days

6.8%

Trailing 12 Months

-24.1%

How does CBIO drawdown profile look like?

CBIO Financial Health

Current Ratio

2.85

Debt/Equity

-0.01

Debt/Cashflow

182.39

CBIO Investor Care

Dividend Yield

1.18%

Dividend/Share (TTM)

0.24

Shares Dilution (1Y)

126.23%

Diluted EPS (TTM)

-1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	105.1M	107.9M	110.7M	113.5M
2022	54.8M	0	0	102.3M
2021	6.0M	5.5M	6.9M	7.3M
2020	9.0M	13.0M	17.0M	20.9M
2018	5.0M	0	0	0
2017	560.5K	562.5K	771.5K	1.0M
2016	1.2M	436.0K	436.0K	398.5K
2015	2.2M	2.8M	2.3M	1.7M
2014	845.5K	1.2M	1.5M	1.8M
2013	38.5M	4.9M	4.1M	523.0K
2012	81.5M	94.4M	76.2M	57.9M
2011	105.2M	105.0M	102.2M	97.6M
2010	0	45.3M	65.5M	85.7M
2009	0	0	0	25.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Catalyst Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 27, 2023	gni hong kong ltd	sold	-	-	-5,371,300	-
Aug 31, 2023	gni group ltd.	back to issuer	-	-	-6,266	-
Aug 31, 2023	lawlor augustine	back to issuer	-	-	-24.573	-
Aug 31, 2023	usman nassim	back to issuer	-	-	-8.456	president & ceo
Aug 31, 2023	usman nassim	back to issuer	-	-	-1.168	president & ceo
Aug 31, 2023	miller seline e.	back to issuer	-	-	-6.5	svp finance; interim cfo & pao
Aug 31, 2023	lawlor augustine	back to issuer	-	-	-24.215	-
Aug 31, 2023	hunt andrea	back to issuer	-	-	-28.228	-
Aug 31, 2023	usman nassim	back to issuer	-	-	-24.541	president & ceo
Aug 09, 2022	miller seline e.	bought	1,527	0.47	3,250	svp finance; interim cfo & pao

Which funds bought or sold CBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-1,696	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-99,788	-	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-29,000	-	-%
Feb 15, 2024	Nantahala Capital Management, LLC	sold off	-100	-32,700	-	-%
Feb 14, 2024	STATE STREET CORP	sold off	-100	-35,015	-	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	sold off	-100	-22,561	-	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-10,837	-	-%
Feb 14, 2024	JOHNSON & JOHNSON	sold off	-100	-32,290	-	-%
Feb 14, 2024	Kynam Capital Management, LP	sold off	-100	-43,435	-	-%
Feb 14, 2024	Arete Wealth Advisors, LLC	sold off	-100	-5,230	-	-%

Are Funds Buying or Selling CBIO?

Are funds buying CBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CBIO

No. of Funds

Unveiling Catalyst Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	lytton laurence w	0%	0	SC 13G/A
Jan 24, 2024	gni group ltd.	85.34%	73,313,885	SC 13D/A
Nov 27, 2023	gni group ltd.	85.36%	73,313,885	SC 13D/A
Nov 01, 2023	gni group ltd.	85.36%	73,313,885	SC 13D/A
Oct 31, 2023	gni group ltd.	16.50%	6,266,521	SC 13D/A
Feb 14, 2023	nantahala capital management, llc	1.4%	438,055	SC 13G/A
Feb 14, 2023	orbimed advisors llc	0%	0	SC 13G/A
Feb 13, 2023	lytton laurence w	7.1%	2,667,333	SC 13G/A
Feb 13, 2023	renaissance technologies llc	3.14%	1,186,986	SC 13G/A
Jan 05, 2023	gni group ltd.	16.6%	6,266,521	SC 13D

Recent SEC filings of Catalyst Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	4	Insider Trading
May 01, 2024	144	Notice of Insider Sale Intent
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 19, 2024	PRE 14A	PRE 14A
Apr 09, 2024	144	Notice of Insider Sale Intent
Apr 08, 2024	144	Notice of Insider Sale Intent
Apr 05, 2024	144	Notice of Insider Sale Intent
Apr 04, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Catalyst Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Catalyst Biosciences Inc News

Latest updates

Catalyst Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3
Revenue	-	-	-	-	-	-	-	2,402,000	2,299,000	1,132,000	1,467,000	2,031,000	893,000	1,658,000	16,366,000	8,342,000	318,000	318,000	111,000	271,000	71,500	109,000
Operating Expenses	10501.1%	172,056,000	1,623,000	2,543,000	-178,000	40,274,000	15,495,000	22,753,000	27,528,000	21,046,000	23,905,000	20,872,000	16,993,000	19,019,000	21,434,000	6,685,000	-	-	-	-	-	-
S&GA Expenses	2082.6%	52,556,000	2,408,000	2,225,000	3,970,000	41,037,000	4,994,000	4,164,000	4,869,000	4,518,000	5,412,000	4,285,000	3,833,000	4,371,000	3,691,000	2,914,000	-	-	-	-	-	-
R&D Expenses	-100.0%	-	415,000	318,000	588,000	-	9,703,000	16,135,000	20,352,000	15,389,000	17,013,000	14,556,000	12,249,000	12,906,000	13,264,000	3,771,000	3,570,500	3,805,000	-	-	-	-
EBITDA Margin	89.7%	-0.66	-6.40	-6.89	1.29	-0.93	-12.99	-11.80	-2.72	-3.42	-3.12	-0.90	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	8,499,000	-	2,000	14,000	5,098,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-4544.2%	-73,193,000	-1,576,000	-2,470,000	274,000	-22,800,000	-14,536,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	89.8%	-0.68	-6.62	-7.12	1.04	-1.19	-13.27	-12.05	-2.96	-3.72	-3.39	-0.98	-	-	-	-	-	-	-	-	-	-
Net Income	-5083.5%	-81,692,000	-1,576,000	-2,472,000	260,000	-27,898,000	-14,536,000	-20,329,000	-25,238,000	-19,928,000	-22,438,000	-18,907,000	-16,033,000	-17,248,000	-4,053,000	-5,042,000	-	-	-	-	-	-
Net Income Margin	88.7%	-0.75	-6.68	-7.18	0.99	-1.24	-12.08	-12.05	-12.49	-14.00	-12.34	-2.68	-	-	-	-	-	-	-	-	-	-
Free Cashflow	1275.1%	37,804,000	-3,217,000	-2,471,000	-6,216,000	-1,475,000	-12,050,000	-17,676,000	-22,092,000	-20,318,000	-24,551,000	-22,309,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1069.6%	117	10.00	12.00	19.00	85.00	31.00	83.00	40.00	56.00	79.00	102	119	95.00	112	124	111	99.00	92.00	101	112	125
Current Assets	1015.0%	57.00	5.00	8.00	14.00	50.00	30.00	81.00	37.00	51.00	74.00	97.00	117	90.00	108	121	108	96.00	89.00	98.00	109	124
Cash Equivalents	1423.1%	34.00	2.00	7.00	8.00	25.00	23.00	75.00	35.00	44.00	59.00	74.00	83.00	30.00	25.00	59.00	70.00	15.00	23.00	17.00	25.00	31.00
Inventory	-	4.00	-	-	-	6.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-	23.00	-	-	0.00	18.00	0.00	0.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	490.4%	38.00	6.00	7.00	11.00	13.00	2.00	4.00	13.00	15.00	18.00	17.00	15.00	19.00	18.00	15.00	13.00	30.00	11.00	8.00	6.00	5.00
Current Liabilities	1024.3%	20.00	2.00	3.00	7.00	12.00	2.00	4.00	13.00	14.00	17.00	16.00	14.00	18.00	17.00	14.00	12.00	29.00	9.00	6.00	4.00	5.00
Shareholder's Equity	296.6%	14.00	4.00	-	-	43.00	29.00	79.00	27.00	59.00	61.00	85.00	104	76.00	94.00	109	98.00	68.00	81.00	93.00	106	120
Retained Earnings	79.4%	-85.50	-414	-413	-410	7.00	-370	-365	-417	-402	-382	-357	-337	-314	-295	-279	-262	-258	-244	-232	-218	-203
Additional Paid-In Capital	-82.3%	68.00	385	385	385	33.00	400	445	444	444	443	442	441	391	390	389	360	327	326	325	324	323
Accumulated Depreciation	-	4.00	-	-	-	4.00	-	-	-	-	-	-	-	-	-	-	-	0.00	-	-	-	0.00
Shares Outstanding	101.7%	77.00	38.00	38.00	38.00	64.00	31.00	31.00	31.00	31.00	30.00	30.00	28.00	22.00	-	-	-	-	-	-	-	-
Minority Interest	-	30.00	-	-	-	30.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	11.00	-	-	-	56.00	-	-	-	135	-	-	-	128	-	-	-	87.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	1275.1%	37,804	-3,217	-2,471	-6,216	42,298	-7,277	-12,294	-12,050	-17,676	-21,600	-20,123	-24,356	-22,114	-13,008	-15,136	-4,790	-8,089	-9,100	-11,466	-14,958	-9,011
Share Based Compensation	6924.5%	6,884	98.00	89.00	210	12,281	224	346	515	683	713	983	1,026	920	1,068	834	805	671	801	903	829	740
Cashflow From Investing	-Infinity%	-24,966	-	4,795	411	-69,189	-	52,871	2,504	2,866	7,038	10,704	27,581	27,551	-21,267	-24,042	27,421	440	14,628	3,661	8,663	4,155
Cashflow From Financing	1131.1%	15,240	-1,478	-3,500	-7,762	-	-45,027	-	16.00	-	98.00	-4.00	49,459	-	-75.00	28,087	32,364	-	92.00	129	106	71.00
Dividend Payments	-100.0%	-	1,500	3,500	7,764	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CBIO Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 113,450	$ 102,290
Operating expenses:
Cost of revenues	4,636	4,793
Selling and marketing	61,159	54,238
Research and development	13,780	16,686
General and administrative	14,662	17,370
Acquired in-process research and development	83,104
Divestiture losses	2,711
Loss on disposal of property and equipment	628	4
Total operating expenses	180,680	93,087
Income (Loss) from operations	(67,230)	9,203
Other income (expense), net:
Interest income, net	1,044	726
Other Income	1,076	857
Change in fair value of warrant liability	(9,261)
Other expenses	(2,594)	(1,374)
Income (loss) before income taxes	(76,965)	9,412
Provision for income taxes	(8,515)	(5,098)
Net (loss) income from operations	(85,480)	4,314
Net income attributable to noncontrolling interest	7,453	2,012
Net (loss) income attributable to common stockholders	$ (92,933)	$ 2,302
Net (loss) income per share attributable to common stockholders, basic	$ (1.41)	$ 0.04
Net (loss) income per share attributable to common stockholders, diluted	$ (1.41)	$ 0.03
Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, basic	65,831,675	63,588,119
Weighted average shares used in calculating net (loss) income per share attributable to common stockholders, diluted	65,831,675	75,686,406
Other comprehensive (loss) income:
Net (loss) income from operations	$ (85,480)	$ 4,314
Foreign currency translation adjustments	(1,484)	(4,928)
Comprehensive loss from operations	(86,964)	(614)
Net income attributable to noncontrolling interest	7,453	2,012
Foreign currency translation adjustments attributable to noncontrolling interest	(647)	(2,170)
Comprehensive income (loss) attributable to noncontrolling interest	6,806	(158)
Comprehensive (loss) attributable to common stockholders	$ (93,770)	$ (456)

CBIO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 33,509	$ 25,175
Accounts and note receivables, net	15,552	17,136
Inventories, net	4,281	6,122
Prepaid assets	1,547	377
Other current assets	1,045	843
Total current assets:	57,221	49,653
Property and equipment, net	23,288	17,709
Intangible assets, net	205	297
Right-of-use assets	489	666
Land use rights, net	1,493	1,559
Deferred tax assets	4,695	4,081
Long-term certificates of deposit	23,431	7,394
Other assets, noncurrent	995	3,394
Total assets	116,539	84,753
Current liabilities:
Accounts payable	355	122
Deferred revenue	39	145
Due to related parties	1,369	118
CVR excess closing cash payable	1,085
Accrued expenses and other current liabilities	11,935	9,264
Income tax payable	5,054	2,101
Operating lease liabilities, current	210	492
Total current liabilities:	20,047	12,242
Operating lease liabilities, noncurrent	199	121
Deferred government grants	213	118
CVR derivative liability, noncurrent	4,722
Warrant liability, noncurrent	12,835
Other noncurrent liabilities	49	55
Total liabilities	38,065	12,536
Commitments and Contingencies (Note 13)
Equity:
Common stock, $0.001 par value, 400,000,000 shares authorized; 76,595,616 shares and 63,588,119 shares issued and outstanding at December 31, 2023 and 2022, respectively	77	64
Additional paid-in capital	68,179	32,795
Statutory reserve	3,098	2,660
(Accumulated deficit) retained earnings	(85,538)	7,395
Accumulated other comprehensive loss	(1,644)	(392)
Total Gyre stockholders' (deficit) equity	(15,828)	42,522
Noncontrolling interest	29,777	29,695
Total equity	13,949	72,217
Total liabilities, convertible preferred stock, and equity	116,539	$ 84,753
GC Biopharma Corp
Current assets:
Long-term receivable from GCBP	4,722
GNI
Current assets:
Other receivables from GNI	1,287
Convertible Preferred Stock
Current liabilities:
Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; 13,151 shares and nil shares issued and outstanding at December 31, 2023 and 2022, respectively	$ 64,525

About Catalyst Biosciences Inc

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

CEO	Dr. Nassim Usman Ph.D.
WEBSITE	catalystbiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	7

Catalyst Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Catalyst Biosciences Inc? What does CBIO stand for in stocks?

CBIO is the stock ticker symbol of Catalyst Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Catalyst Biosciences Inc (CBIO)?

As of Tue May 07 2024, market cap of Catalyst Biosciences Inc is 1.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CBIO stock?

You can check CBIO's fair value in chart for subscribers.

What is the fair value of CBIO stock?

You can check CBIO's fair value in chart for subscribers. The fair value of Catalyst Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Catalyst Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Catalyst Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CBIO is over valued or under valued. Whether Catalyst Biosciences Inc is cheap or expensive depends on the assumptions which impact Catalyst Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CBIO.

What is Catalyst Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, CBIO's PE ratio (Price to Earnings) is -21.32 and Price to Sales (PS) ratio is 16.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CBIO PE ratio will change depending on the future growth rate expectations of investors.